Absci (ABSI) Stock Price, News & Analysis

Company Overview

Absci Corporation is a biotechnology company that uses generative artificial intelligence and integrated laboratory technologies to discover and develop new medicines. The company focuses primarily on biologics, including antibody-based therapies, and aims to accelerate the process of moving from drug concept to candidate development.

Absci’s platform combines artificial intelligence models with biological data generation and laboratory experimentation. Its capabilities include protein and antibody design, target and candidate evaluation, and the development of cell lines and manufacturing processes intended to support biologic drug production. The company also works with pharmaceutical and biotechnology partners on drug discovery and development programs.

Founded in 2011, Absci is headquartered in Vancouver, Washington, and serves the global biopharmaceutical industry through its technology platform and collaborations. Founder Sean McClain serves as the company’s chief executive officer.

Key Stats

• Today's Range: $10.83 to $11.35
• 50-Day Range: $6.90 to $11.07
• 52-Week Range: $2.24 to $12.06
• Volume: 3.38 million shs
• Average Volume: 3.85 million shs
• Market Capitalization: $1.90 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.71
• Consensus Rating: Moderate Buy

Absci Stock Analysis - MarketRank™

Absci scored higher than 54% of companies evaluated by MarketBeat, and ranked 410th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Absci has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Absci has a consensus price target of $13.71, representing about 23.9% upside from its current price of $11.07.

Amount of Analyst Coverage

Absci has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Absci are expected to grow in the coming year, from ($0.74) to ($0.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Absci is -13.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Absci is -13.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Absci has a P/B Ratio of 8.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.26% of the float of Absci has been sold short.

Short Interest Ratio / Days to Cover

Absci has a short interest ratio ("days to cover") of 14.44, which indicates bearish sentiment.

Change versus previous month

Short interest in Absci has recently increased by 1.27%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Absci does not currently pay a dividend.

Dividend Growth

Absci does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.25

News Sentiment

Absci has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Absci this week, compared to 4 articles on an average week.

Search Interest

Only 12 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

16 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 1,500% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Absci insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.52% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ABSI
• CIK: 1672688
• Web: www.absci.com
• Phone: 360-949-1041
• Fax: N/A
• Employees: 140
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Absci: $13.71
• High Price Target: $17.00
• Low Price Target: $10.00
• Potential Upside/Downside: +23.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$115.18 million
• Net Margins: -7,756.38%
• Pretax Margin: -7,756.37%
• Return on Equity: -61.71%
• Return on Assets: -54.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.63
• Quick Ratio: 10.63

Sales & Book Value

• Annual Sales: $2.80 million
• Price / Sales: 678.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.26 per share
• Price / Book: 8.79

Miscellaneous

• Outstanding Shares: 171,610,000
• Free Float: 153,560,000
• Market Cap: $1.90 billion
• Optionable: Optionable
• Beta: 2.27